Here’s How Much You Would Have Made Owning Bio-Techne Stock In The Last 5 Years
Bio-Techne (NASDAQ:TECH) has outperformed the market over the past 5 years by 17.84% on an annualized basis.
The Daily Biotech Pulse: Pfizer Reports Solid Q3 Earnings, Regulatory Setback For Legend, Lilly to Supply Additional COVID-19 Antibody Cocktails To US
Here's a roundup of top developments in the biotech space over the last 24 hours:
Earnings Scheduled For November 2, 2021
Companies Reporting Before The Bell
• Thomson Reuters (NYSE:TRI) is expected to report quarterly earnings at $0.48 per share on revenue of $1.86 billion.
Bio-Techne’s Earnings: A Preview
Bio-Techne (NASDAQ:TECH) is set to give its latest quarterly earnings report on Tuesday, 2021-11-02. Here's what investors need to know before the announcement.
Analysts estimate that Bio-Techne will likely report an Earnings Per Share (EPS) of $1.72
The Week Ahead In Biotech (Oct. 31-Nov. 6): Earnings Pick Up Pace, Eton Awaits Seizure Drug Approval, Kidney Conference, More IPOs In The Pipeline
Biotech stocks rose a third week running in the week ending Oct. 29 amid positive reaction to earnings. Big pharma earnings were mostly better than expected.
Bio-Techne Announces ExoDx Prostate Test Data Publication in the Journal of Prostate Cancer and Prostatic Diseases
Bio-Techne Corporation (NASDAQ:TECH) today announced that Exosome Diagnostics, a Bio-Techne brand, has published important clinical research in the journal Prostate Cancer and Prostatic Diseases,
The Daily Biotech Pulse: Leap, Phio, Silverback Among Early Movers On Oncology Conference Presentations, Aerie Slumps On Mixed Data, Axsome Commences Phase 3 Sleep Disorder Study
Here's a roundup of top developments in the biotech space over the last 24 hours:
Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs Sept. 15)
Keybanc Upgrades Bio-Techne to Overweight, Announces $600 Price Target
Keybanc analyst Paul Knight upgrades Bio-Techne (NASDAQ:TECH) from Sector Weight to Overweight and announces $600 price target.
The Daily Biotech Pulse: NRx Rises On COVID-19 Drug Collaboration, Amgen’s Lung Cancer Drug Conditionally Approved In Canada, Coherus Data Readout
Here's a roundup of top developments in the biotech space over the last 24 hours.
Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs Sept. 13)